Clinical Trial Update: Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study evaluating TAS-119 in combination with paclitaxel in patients with advanced solid tumors. The trial status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• TAS-119 (tas-119)

Snippet

Sponsor: Taiho Oncology, Inc. | Conditions: Advanced Solid Tumors | Phase 1 | Status: TERMINATED